OTC:MDNC
Medinotec Inc.
A high-growth medical nutrition and wound care provider that recently transitioned to profitability with a 147% year-over-year revenue increase.
Key Metrics
Investment Thesis
Bull Case
Investors should consider MDNC due to its explosive revenue growth trajectory and recent attainment of profitability, suggesting the company has passed the early-stage valuation trap. The strong positive cash flow relative to net income indicates high quality earnings and a healthy balance sheet with current assets of $6.4M against only $1.5M in current liabilities.
Bear Case
Caution is warranted given the small market capitalization inherent in OTC-traded stocks and the recent transition from discontinued operations which reported a loss of -$1.7M, potentially obscuring true underlying performance. The reliance on a relatively narrow set of business segments creates concentration risk if regulatory reimbursement rates for wound care or nutrition products are reduced by federal or state bodies.
About Medinotec Inc.
Medinotec Inc. (MDNC) is a specialized healthcare provider offering medical nutrition support, wound care management, and clinical services primarily across North America. The company has demonstrated robust growth, with revenue expanding from $1.0M in 2023 to $9.1M in 2025, driven by strong operational performance and successful market penetration.
Analysis
Management Discussion
Management successfully executed a turnaround strategy, evidenced by the shift from a net loss of -$0.4M in 2023-2024 to a net profit of $2.2M in 2025. Operational efficiency improvements are highlighted by a strong cash flow from operations of $877,834, which significantly outpaced the capital expenditures and interest expenses.
Industry Overview
The medical nutrition and home healthcare sector is experiencing a structural shift towards consumer-directed services, benefiting from an aging population with chronic conditions requiring specialized dietary management. This tailwind supports companies that can offer integrated solutions combining nutritional therapy with advanced wound care technologies to reduce overall healthcare system costs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $999.6K | $5.0M | $9.1M |
| Cost of Revenue | $-417.8K | $-2.6M | $-4.3M |
| Gross Profit | $581.8K | $2.4M | $4.9M |
| Operating Expenses | $1.0M | $-1.8M | $-1.7M |
| Operating Income | $-465.4K | $600.6K | $3.2M |
| R&D | $64.9K | $-22.4K | $-91.1K |
| G&A | $640.6K | $-1.7M | $-1.4M |
| Marketing | $53.8K | $-84.6K | $-113.2K |
| D&A | $53.6K | $88.2K | $73.8K |
| Other OpEx | $288.0K | $-63.9K | $-73.8K |
| Non-Operating Income | $73.9K | $-854.3K | $-167.4K |
| Interest Expense | $156.1K | $-277.2K | $-176.4K |
| Interest Income | — | $60.6K | $73.5K |
| Pre-Tax Income | $-391.5K | $-253.8K | $3.0M |
| Income Tax | $-38.7K | $-150.9K | $-864.7K |
| Continuing Ops | $-352.7K | $-102.9K | $3.9M |
| Discontinued Ops | $0 | $-301.8K | $-1.7M |
| Net Income | $-352.7K | $-404.7K | $2.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-352.7K | $-404.7K | $2.2M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $3.4M | $4.4M | $6.4M |
| Accounts Receivable | $21.1K | $589.8K | $2.6M |
| Other Current Assets | $3.3M | $3.8M | $3.8M |
| Long-Term Assets | $1.1M | $425.0K | $385.8K |
| PP&E (Net) | $406.9K | $320.1K | $348.5K |
| Operating Leases | — | $62.0K | $37.3K |
| Other LT Assets | $714.1K | $42.9K | $0 |
| Total Assets | $4.5M | $4.8M | $6.8M |
| Current Liabilities | — | $827.5K | $1.5M |
| Current Leases | — | $24.3K | $28.1K |
| Other Current Liab | — | $803.1K | $1.5M |
| Long-Term Liabilities | — | $1.8M | $1.0M |
| LT Operating Leases | — | $39.7K | $12.7K |
| Other LT Liab | — | $1.8M | $1.0M |
| Total Liabilities | $1.9M | $2.6M | $2.5M |
| Shareholders' Equity | $2.6M | $2.2M | $4.3M |
| Paid-In Capital | $3.3M | $3.3M | $3.3M |
| AOCI | $84.6K | $100.4K | $44.6K |
| Total L&E | $4.5M | $4.8M | $6.8M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-352.7K | $-404.7K | $2.2M |
| Non-Cash Adjustments | $-105.7K | $982.4K | $666.4K |
| Working Capital Changes | $-32.1K | $-563.5K | $-1.9M |
| Cash from Operations | $-490.5K | $14.2K | $877.8K |
| Capital Expenditures | $55.3K | $-2.3K | $-89.0K |
| Cash from Investing | $-529.7K | $10.1K | $-89.0K |
| Debt Issuances | $279.1K | — | — |
| Cash from Financing | $3.6M | $-8.1K | $-894.5K |
| FX Effect | $139.0K | $-34.8K | $66.4K |
| Net Change in Cash | $2.7M | $-18.5K | $-39.2K |
| Beginning Cash | $131.6K | $2.8M | $2.8M |
| Ending Cash | $2.8M | $2.8M | $2.8M |
Frequently Asked Questions
How does Medinotec Inc. make money?
Core revenue streams include Medical Nutrition Therapy providing specialized dietary solutions for chronic conditions, Advanced Wound Care delivering treatment for complex injuries, and Clinical Services offering diagnostic and therapeutic support in outpatient settings.
What are the main risks for MDNC?
Significant volatility in revenue growth as the company scales from a $1M to $9M base, potential regulatory changes affecting medical device reimbursement rates, sensitivity to supply chain disruptions for specialized nutrition products, and the risk of margin compression due to increased competition in the growing home health market.
What is MDNC's competitive advantage?
The company leverages proprietary clinical protocols that improve patient outcomes while reducing hospital readmission rates, a highly scalable direct-to-consumer sales model that minimizes distribution costs, and a growing portfolio of exclusive partnerships with regional healthcare systems.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.